IRCT20200105046010N31招募中未知
In- Vivo Bioequivalence study of Ticagrelor tablet 90mg Abidi Pharmaceuticals (BRILAVUS® 90mg Tablets) with brand drugs (BRILINTA® 90mg, AstraZeneca UK) in Iranian healthy volunteers.
ABIDI Pharmaceutical Company0 个研究点目标入组 24 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 60 years（—）
- 性别
- All
入选标准
- •General health
- •Body mass index(18-28)
- •Informed consent
- •Age(18-60)
排除标准
- •A history of cardiovascular disease
- •A history of liver & kidney disease
- •Alcohol & Drug addiction
- •Hypersensitivity to the drug
研究者
相似试验
尚未招募
不适用
In vivo Bioequivalence study of Ticagrelor TabletIn the present study, no diseases will be examined and products will be administered by healthy volunteers..IRCT20210519051345N1Tabriz University of Medical Sciences24
招募中
不适用
In-vivo Bioequivalence Test of Ticagrelor® tablet with brand drugs (BRILINTA® AstraZeneca UK).IRCT20200105046010N28ARENA Pharmaceutical Company24
尚未招募
Unknown
Comparative in vivo evaluation of 2 Ticagrelor 90 mg F.C. Tablet and Brilinta® 90 mg F.C. Tablet formulations.ong term (current) use of antithrombotics/antiplatelets.Long term (current) use of antithrombotics/antiplateletsZ79.02IRCT20180620040164N54Zist Arvand Pharme Ltd.24
已完成
不适用
Bioequivalence study of Ticagrelor 90mgIRCT20200623047902N9Kimia Ara Heram company24
招募中
2 期
The short-term outcomes of Ticagrelor versus Clopidogrel in patients with myocardial infarctioAcute myocardial infarction.Other current complications following acute myocardial infarctionI23.8IRCT20180205038626N9Rasht University of Medical Sciences128